How have SUMM shares performed in 2024?

Summit Therapeutics' stock was trading at GBX 20.50 at the start of the year. Since then, SUMM shares have increased by 0.0% and is now trading at GBX 20.50. View the best growth stocks for 2024 here .

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) announced its quarterly earnings data on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.00) by $1.00.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT) , American Airlines Group (AAL) , Acadia Healthcare (ACHC) , Diana Shipping (DSX) , 2570 (JLF.L) (JLF) , National Fuel Gas (NFG) , Tailored Brands (TLRD) , The Weir Group (WEIR) and Acacia Mining (ABGLF) .

How do I buy shares of Summit Therapeutics?

Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:SUMM

Summit Therapeutics (SUMM) Share Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free SUMM Stock Alerts

GBX 20.50

0.00 (0.00%)

(As of 02/21/2020)

Compare

Today's Range: 18
▼
20.50
50-Day Range: 20.50
▼
20.50
52-Week Range: 18
▼
32.50

Volume: 280,318 shs
Average Volume: 382,504 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Summit Therapeutics alerts:

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Summit Therapeutics Stock (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

SUMM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SUMM Stock News Headlines

April 18, 2024 | finance.yahoo.com

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit

April 16, 2024 | finance.yahoo.com

2024 DTA Summit Agenda is LIVE!!

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 13, 2024 | investing.com

Summit Therapeutics appoints genomics expert to board

April 9, 2024 | msn.com

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

April 8, 2024 | msn.com

Carisma Therapeutics to Present at Upcoming Healthcare Conferences

April 5, 2024 | finance.yahoo.com

In coordination with DoH J.P. Morgan's Life Sciences Private Capital announces Life Sciences Innovation Summit 2024 finalists ahead of ADGHW

April 4, 2024 | finance.yahoo.com

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

April 2, 2024 | msn.com

France’s Superprod Group Acquires Luxembourg Animation Duo Studio 352 & Mélusine Productions

April 2, 2024 | finance.yahoo.com

Spotlighting Excellence: Keiretsu Forum Curates Premiere Investment Opportunities for the 2024 Angel Capital Association Innovation Funders Showcase

March 29, 2024 | msn.com

Why Summit Therapeutics Stock Crushed the Market This Week

March 28, 2024 | benzinga.com

Akeso Marks Profit Milestone With Swift Rights Issue

March 27, 2024 | finance.yahoo.com

Coave Therapeutics to Present at Upcoming Conferences

March 27, 2024 | msn.com

Lukashenko says concert hall attackers first headed for Belarus, contradicting Putin

March 27, 2024 | msn.com

Police probe possible bomb threat at Simi Valley surgery center

March 27, 2024 | markets.businessinsider.com

Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment

March 26, 2024 | finanznachrichten.de

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

March 26, 2024 | seekingalpha.com

Wall Street Breakfast Podcast: Lucid Group Secures $1B Investment

March 25, 2024 | finance.yahoo.com

Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment

March 22, 2024 | stockhouse.com

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

March 21, 2024 | msn.com

Scientists Working on Drug to Indefinitely Delay Menopause

March 20, 2024 | msn.com

New menopause prevention drug could delay onset, boost women’s longevity

March 18, 2024 | finance.yahoo.com

RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit

March 15, 2024 | finance.yahoo.com

CRBP Mar 2024 30.000 put

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Cresco Labs (OtherCRLBF)

March 13, 2024 | markets.businessinsider.com

TVM Capital Life Science to Participate in LSI USA ’24 Emerging Medtech Summit 2024

See More Headlines

Receive SUMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 6/12/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Current Symbol: LON:SUMM
CUSIP: N/A
CIK: N/A
Web: www.summitplc.com
Phone: +44-1235-443939
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Glyn O. Edwards (Age 63)
CEO & Exec. Director
Mr. Erik Ostrowski (Age 46)
Chief Financial Officer
Prof. David Roblin (Age 53)
COO, Chief Medical Officer and Pres of R&D
Prof. Kay Davies (Age 69)
Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Ms. Michelle Avery
Director of Investor Relations

Key Competitors

View All Competitors

SUMM Stock Analysis - Frequently Asked Questions

How have SUMM shares performed in 2024?: Summit Therapeutics' stock was trading at GBX 20.50 at the start of the year. Since then, SUMM shares have increased by 0.0% and is now trading at GBX 20.50.
View the best growth stocks for 2024 here.
How were Summit Therapeutics' earnings last quarter?: Summit Therapeutics PLC (LON:SUMM) announced its quarterly earnings data on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.00) by $1.00.
What other stocks do shareholders of Summit Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF).
How do I buy shares of Summit Therapeutics?: Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SUMM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial